Not indicated for mild GI complaints eg, nervous dyspepsia. Do not administer concomitantly w/ other medications through the same IV line. Always flush w/ either 0.9% NaCl or 5% dextrose soln before & after administration. Discontinue IV administration as soon as oral treatment is possible. Monitor liver enzymes of patients w/ severe hepatic impairment, particularly on long-term use. Discontinue treatment if liver enzymes increased. Exclude malignancy when gastric ulcer is suspected or present. Discontinue if acute interstitial nephritis develops or subacute cutaneous lupus erythematosus occurs. Increased risk of GI infections eg, Salmonella & Campylobacter;
C. difficile-associated diarrhea. High-dose & long-term therapy may increase risk for osteoporosis-related fractures of the hip, wrist or spine. Hypomagnesemia; consider monitoring Mg levels prior to initiation of treatment & periodically. May contribute to the development of cyanocobalamin deficiency in prolonged use (eg, >3 yr). Atrophic gastritis in long-term use particularly in patients w/
H. pylori. Increased risk of developing community-acquired pneumonia. Anaphylaxis & other serious reactions eg, erythema multiforme, SJS, & TEN. False +ve urine screening tests for tetrahydrocannabinol. Engaging in activities requiring alertness eg, operating machinery or driving a car. Hepatic & renal impairment. Pregnancy & lactation. Childn <1 yr.
Sign Out
